Newsbenzinga
Small-Cap ProQR Therapeutics Secures Funding From Eli Lilly On Early Trial Success
· Published
Article summary
ProQR reported positive AX-0810 Phase 1 data and raised $50 million, with Eli Lilly joining a concurrent share purchase.
An excerpt from the original article.
Comments —
Loading comments…